/
PTCT
$81.57+$0.00 (+0.00%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$7.0B
83M shares
52-week range
$43.18 – $87.50
87% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$37.81
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $264.7M | $307.0M | $380.8M | $538.6M | $698.8M | $937.8M | $806.8M | $1.73B |
| Cost of revenue | $12.7M | $12.1M | $18.9M | $32.3M | $44.7M | $65.5M | $57.4M | $71.8M |
| Gross profit | $252.1M | $294.8M | $361.8M | $506.3M | $654.1M | $872.3M | $749.4M | $1.66B |
| Gross margin | 95.2% | 96.0% | 95.0% | 94.0% | 93.6% | 93.0% | 92.9% | 95.9% |
| R&D | $172.0M | $257.5M | $477.6M | $540.7M | $651.5M | $666.6M | $534.5M | $455.2M |
| Operating income | −$115.7M | −$241.2M | −$431.8M | −$374.4M | −$447.4M | −$439.5M | −$302.6M | $856.5M |
| EBITDA | −$89.5M | −$195.3M | −$303.1M | −$368.2M | −$367.8M | −$330.3M | −$120.5M | $887.7M |
| Net income | −$128.1M | −$251.6M | −$438.2M | −$523.9M | −$559.0M | −$626.6M | −$363.3M | $682.6M |
| Net margin | -48.4% | -82.0% | -115.1% | -97.3% | -80.0% | -66.8% | -45.0% | 39.4% |
| EPS (diluted) | -2.75 | -4.27 | -6.64 | -7.43 | -7.79 | -8.37 | -4.73 | 7.78 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.2B | $0.89 | $0.57–$1.15 | 7 |
| 2027 | $1.3B | $2.50 | $1.54–$3.74 | 7 |
| 2028 | $1.6B | $2.84 | $-0.41–$5.02 | 8 |
| 2029 | $1.7B | $4.22 | $3.57–$4.93 | 6 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
PTC Therapeutics, Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
www.ptcbio.com- Employees
- 991
- IPO / List date
- Jun 20, 2013
- HQ
- WARREN, NJ
Held by traders on TradeandTell
No one on the platform currently holds PTCT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 533,300 | $36.3M |
| Bridgewater Associatesas of 2025-12-31 | 16,229 | $1.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PTCT yet.
